We are developing and evaluating an early-stage technology to target the sources of inflammation and inflammatory processes in osteoarthritis.

Osteoarthritis is a degenerative, chronic, inflammatory disease, resulting in the destruction of the joints. Osteoarthritis (OA) is the most common musculo-skeletal disease, it is anticipated that by 2050, 130 millions people will suffer from OA*. 4P 004 is being developed in an effort to help patients affected by this disease. At this stage, the proof-of-concept and proof-of-mechanism have been established and the product will now be evaluated for basic safety.

 

4p-pharma-inflammation

 

* Rachel Wittenauer, Lily Smith, and Kamal Aden. “Priority Medicines for Europe and the World “A Public Health Approach to Innovation”-Background Paper 6.12 Osteoarthritis“, 2013.